Published on 8 Nov 2023 on Zacks via Yahoo Finance
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
Theravance Biopharma, Inc. (TBPH) reported third-quarter 2023 adjusted net loss of 1 cent per share, which was narrower than the Zacks Consensus Estimate of a loss of 10 cents.
The reported loss excludes share-based compensation expense and non-cash interest expense. In the year-ago quarter, the company had incurred a loss of 9 cents per share.
The bottom line improved owing to higher collaboration revenues from Viatris VTRS and reduced research & development (R&D) and selling, general & administrative (SG&A) cost.